Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer

Nobuyoshi Takeshita, Toru Fukunaga, Masayuki Kimura, Yuji Sugamoto, Kentaro Tasaki, Isamu Hoshino, Takumi Ota, Tetsuro Maruyama, Tomohide Tamachi, Takashi Hosokawa, Yo Asai, Hisahiro Matsubara

Hisa Hiro Matsubara, Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan

Author contributions: Takeshita N and Matsubara H planned the report; Takeshita N, Fukunaga T, Kimura M, Sugamoto Y, Tasaki K, Hoshino I, Ota T, Maruyama T, Tamachi T, Hosokawa T and Asai Y performed the treatment for this case; and Takeshita N wrote the paper.

Institutional review board statement: The case report was reviewed and approved by Numazu City Hospital Institutional Review Board.

Informed consent statement: The patient provided informed written consent prior to treatment and publication.

Conflict-of-interest statement: We have no financial relationships to disclose.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Nobuyoshi Takeshita MD, PhD, Department of Surgery, Numazu City Hospital, Shizuoka, Shizuoka 410-0302, Japan. ntakeshita1225@gmail.com
Telephone: +81-55-9245100
Fax: +81-55-9245133

Received: March 19, 2015
Peer-review started: March 20, 2015
First decision: July 17, 2015

Abstract

A 66-year-old female presented with the main complaint of defecation trouble and abdominal distention. With diagnosis of rectal cancer, cSS, cN0, cH0, cP0, cM0, cStage II, Hartmann’s operation with D3 lymph node dissection was performed and a para-aortic lymph node and a disseminated node near the primary tumor were resected. Histological examination showed moderately differentiated adenocarcinoma, pSS, pN3, pH0, pP1, pM1 (para-aortic lymph node, dissemination) fStage IV. After the operation, the patient received chemotherapy with FOLFIRI regimen. After 12 cycles of FOLFIRI regimen, computed tomography (CT) detected an 11 mm of liver metastasis in the postero-inferior segment of right hepatic lobe. With diagnosis of liver metastatic recurrence, we performed partial hepatectomy. Histological examination revealed moderately differentiated adenocarcinoma as a metastatic rectal cancer with cut end microscopically positive. After the second operation, the patient received chemotherapy with TS1 alone for 2 years. Ten months after the break, CT detected a 20 mm of para-aortic lymph node metastasis and a 10 mm of lymph node metastasis at the hepato-duodenal ligament. With diagnosis of lymph node metastatic recurrences, we performed lymph node dissection. Histological examination revealed moderately differentiated adenocarcinoma as metastatic rectal cancer in para-aortic and hepato-duodenal ligament areas. After the third operation, we started chemotherapy with modified FOLFOX6 regimen. After 2 cycles of modified FOLFOX6 regimen, due to the onset of neutropenia and liver dysfunction, we switched to capecitabine alone.
and continued it for 6 mo and then stopped. Eleven months after the break, CT detected two swelling 12 mm of lymph nodes at the left supraclavicular region. With diagnosis of Virchow lymph node metastatic recurrence, we started chemotherapy with capecitabine plus bevacizumab regimen. Due to the onset of neutropenia and hand foot syndrome (Grade 3), we managed to continue capecitabine administration with extension of interval period and dose reduction. After 2 years and 2 mo from starting capecitabine plus bevacizumab regimen, Virchow lymph nodes had slowly grown up to 17 mm. Because no recurrence had been detected besides Virchow lymph nodes for this follow up period, considering the side effects and quality of life, surgical resection was selected. We performed left supraclavicular lymph node dissection. Histological examination revealed moderately differentiated adenocarcinoma as a metastatic rectal cancer. After the fourth operation, the patient selected follow up without chemotherapy. Now we follow up her without recurrence and keep her quality of life high.

**Key words:** Rectal cancer; Surgical resection; Virchow lymph node metastasis; Para-aortic lymph node metastasis; Liver metastasis; Peritoneal carcinomatosis; Long-term survival

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** A 66-year-old female who had para-aortic lymph node metastasis and peritoneal dissemination of rectal cancer underwent Hartmann’s operation. Beginning from stage IV, liver metastasis, para-aortic and hepato-duodenal ligament lymph node and Virchow lymph node recurrence were detected during follow up period. According to the previous reports, the resection of these severe recurrences is controversial. We conducted four operations during 8 years for Stage IV rectal cancer and its recurrences. Finally, there is no recurrence radiologically. It should be considered that surgical resection may bring longer term survival especially in cases with difficulty in management of chemotherapy.

Takeshita N, Fukunaga T, Kimura M, Sugamoto Y, Tasaki K, Hoshino I, Ota T, Maruyama T, Tamachi T, Hosokawa T, Asai Y, Matsubara H. Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer. *World J Gastroenterol* 2015; 21(44): 12722-12728 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i44/12722.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i44.12722

**INTRODUCTION**

In recent decades, great progress has been achieved in the management of colorectal cancer, especially in the development of new chemotherapeutic agents and surgical technique. The prognosis of patients with stage IV colorectal cancer and its recurrence used to be very poor, but depending on metastatic site, surgical resection combined with chemotherapy may bring longer term survival nowadays. Now, we herein report a case of four times successful resections during 8 years for Stage IV rectal cancer and its liver, para-aortic, hepato-duodenal ligament and Virchow lymph node metastases.

**CASE REPORT**

A 66-year-old female presented with the main complaint of defecation trouble and abdominal distention. Abdominal X-ray showed much of colon gas and computed tomography (CT) showed hypertrophy and obstruction of rectum and severe colonic dilatation (Figure 1A). No metastasis was revealed in the liver and lungs. Radiographical examination revealed rectosigmoid obstruction and a decompressive tube couldn’t pass the stenosis (Figure 1B). Mild dehydration was shown, but other laboratory tests and serum levels of carcino-embryonic antigen and carbohydrate antigen 19-9 were all within normal limits. The preoperative diagnosis was rectal cancer, cSS, cN0, cH0, cP0, cM0 cStage II by the Japanese Classification of Colorectal Carcinoma (JCCC) [1]. Hartmann’s operation with D3 lymph node dissection was performed and a swelling para-aortic lymph node and a disseminated node near the primary tumor were resected. R0 (microscopically negative margin) surgery was achieved. Histological examination showed moderately differentiated adenocarcinoma, pSS, pN3, pH0, pP1, pM1 (para-aortic lymph node, dissemination) fStage IV by JCCC (1) (Figure 1C and D). After the operation, the patient received chemotherapy with FOLFIRI regimen (starting doses: irinotecan at 150 mg/m², folinic acid at 200 mg/m², fluorouracil (5-FU) bolus at 400 mg/m² on day 1 and 5-FU continuous intravenous infusion at 2400 mg/m² on days 1-2, every two weeks). Between 12 cycles of FOLFIRI regimen, due to the onset of neutropenia (Grade 3), we managed to continue FOLFIRI regimen with extension of interval period and dose reduction. After 12 cycles of FOLFIRI regimen (one year after first operation), CT detected an 11 mm of liver metastasis in the postero-inferior segment of right hepatic lobe (Figure 2A and B). With diagnosis of liver metastatic recurrence, we performed partial hepatectomy. Histological examination revealed moderately differentiated adenocarcinoma as a metastatic rectal cancer with cut end microscopically positive (R1) (Figure 2C). After the second operation, the patient received chemotherapy with TS1 alone for 2 years. For 2 years, due to the onset of neutropenia (Grade 3), we managed to continue TS1 administration with extension of interval period and dose reduction. Finally, because of no recurrence, TS1 administration was stopped by mutual consultation between the patient.
Computed tomography showed hypertrophy and obstruction of rectum and severe colonic dilatation (A); Radiographical examination revealed rectosigmoid obstruction (B); and Histological examination showed moderately differentiated adenocarcinoma, pSS, pN3, pH0, pP1, pM1 (para-aortic lymph node, dissemination) fStage IV (C and D).

Computed tomography detected an 11 mm of liver metastasis in the posteroinferior segment of right hemic lobe (A and B); and Histological examination revealed moderately differentiated adenocarcinoma as a metastatic rectal cancer with cut end microscopically positive (C).
and us. Ten months after the break, CT detected a 20 mm of para-aortic lymph node metastasis and a 10 mm of lymph node metastasis at the hepato-duodenal ligament (Figure 3A and B). Positron emission tomography was performed and detected the recurrences at the same lesions (Figure 3C). With diagnosis of lymph node metastatic recurrences, we performed lymph node dissection (4 years after first operation). R0 surgery was achieved. Histological examination revealed moderately differentiated adenocarcinoma as metastatic rectal cancer in para-aortic and hepato-duodenal ligament areas. After the third operation, we started chemotherapy with modified FOLFOX6 regimen (starting doses: oxaliplatin at 85 mg/m^2, intravenous infusion folinic acid at 200 mg/m^2, bolus 5-FU at 400 mg/m^2 on day 1 and continuous intravenous infusion of 5-FU at 2400 mg/m^2 on days 1-2, every two weeks). After 2 cycles of modified FOLFOX6 regimen, due to the onset of neutropenia and liver dysfunction, we switched to capecitabine alone and continued it for 6 mo and then stopped. Eleven months after the break, CT detected two swelling 12 mm of lymph nodes at the left supraclavicular (Figure 4A). With diagnosis of Virchow lymph node metastatic recurrence, we started chemotherapy with capecitabine plus bevacizumab regimen (5 years and 6 mo after first operation). Due to the onset of neutropenia and hand foot syndrome (Grade 3), we managed to continue capecitabine administration with extension of interval period and dose reduction. After 2 years and 2 mo from starting capecitabine plus bevacizumab regimen, Virchow lymph nodes had slowly grown up to 17 mm (Figure 4B). Because no recurrence had been detected besides Virchow lymph nodes for this follow up period, considering the side effects and quality of life, surgical resection was selected by mutual consultation between the patient and us. We performed left supraclavicular lymph node dissection (8 years after first operation). R0 surgery was achieved. Histological examination revealed moderately differentiated adenocarcinoma as a metastatic rectal cancer. After the fourth operation, the patient selected follow up without chemotherapy. Now we follow up her without recurrence and keep her quality of life high. Figure 5 shows the clinical course.

**DISCUSSION**

As a result of the significant advances in the clinically available chemotherapeutic agents, such as 5-FU, leucovorin and oxaliplatin combination chemotherapy (FOLFOX) and 5-FU, leucovorin and irinotecan combination chemotherapy (FOLFIRI), the median survival time of patients with metastatic colorectal cancer improved to > 20 mo in a recently published report[2]. Furthermore, recently, bevacizumab and anti-
EGFR monoclonal antibody have been reported to improve the survival times of patients\[3,4\]. Many kinds of chemotherapeutic agents are available, but it is important to manage side effects and keep quality of life high\[5\].

In colorectal cancer, up to about 20% of all patients present with stage IV disease at initial diagnosis\[6,7\]. Liver, lung and peritoneum are the most frequently observed metastatic site. It was reported that sites of metastasis were liver 85%, lung 4% and peritoneum 10\%\[7\]. For patients with resectable metastatic lesion, R0 surgery was thought to lead to improvement of prognosis. In the cases of liver or lung metastasis, this policy has been well acceptable and 5 year survival rates were reported to be above 60\%\[8,9\]. Peritoneal carcinomatosis is thought to result from peritoneal spread of cancer cells or seeding of the peritoneum during surgery, and it has been associated with a median survival time of 7 mo\[10\].

Recently, the combination of multimodality therapy...
and cytoreduction surgery has been accepted and using this approach, median survival exceeding 60 mo has been reported[11]. Although in the limited cases, surgical resection was acceptable option for the patient with peritoneal carcinomatosis from colorectal cancer.

Extra-mesenteric lymph node metastasis such as para-aortic lymph node and lateral pelvic lymph node metastasis are thought to be poor prognostic factors and the indication of surgical resection for these conditions is controversial[12]. On the other hand, para-aortic lymph node recurrence after curative surgery for colorectal cancer is more rare condition. It was reported that isolated para-aortic lymph node recurrence was identified in 1.3% of the patients who underwent curative surgery for colorectal cancer, and the median survival time from para-aortic lymph node recurrence for the resected patients was 34 mo, whereas it was 12 mo for those who did not undergo resection[13]. Lymph node metastasis outside the mesenteric lesion may represent metastasis from metastasis. Traditionally, metastatic disease in the hilar or para-aortic lymph nodes has been considered a strong relative contraindication to surgery due to poor prognosis. However, more recently, with more effective chemotherapy, the role of resection of these extra hepatic lymph node metastasis has been reconsidered. The patients of colorectal liver metastasis with lymph node metastasis in hepato-duodenal ligament and retro-pancreatic area had a 5-year survival greater than 30%. These data may have important implications to help select patients for surgical resection. On the other hand, these patients with lymph node metastasis in para-aortic area had median survival of only 17 mo and every patient experienced a recurrence. On the basis of these data, surgical resection for the cases with para-aortic lymph node metastasis should be more controversial[14]. Left supraclavicular lymph node is often called Virchow lymph node. The lymphatic vessels including the thoracic duct arrive at the Virchow lymph node, and this is recognized as being “final destination” of lymph nodes[15]. The metastasis to this lesion is thought to be extremely poor prognostic risk factor and the evidence of the treatment option for this is insufficient. There are some reports about synchronous or metachronous metastasis of Virchow lymph node which were treated by chemotherapy or chemoradiotherapy and achieved good prognosis[16,17].

In this case, para-aortic lymph node metastasis and peritoneal dissemination of rectal cancer were revealed in first operation. Beginning from stage IV, three times operations were done for liver metastatic recurrence, para-aortic and hepato-duodenal ligament lymph node recurrence and Virchow lymph node recurrence. According to previous reports, the resection of liver metastatic recurrence was acceptable, but the indication of the extrahepatic disease, such as para-aortic, hepato-duodenal ligament and Virchow lymph node is controversial. Furthermore, para-aortic and Virchow lymph node recurrences may be thought to be extremely poor prognostic factors. Meanwhile, this patient had difficulty with the management of chemotherapeutic side effects. In fact, extension of interval period and dose reduction of chemotherapy was necessary and her quality of life was low due to the onset of neutropenia and other side effects. As to Virchow lymph node metastasis, during the period of chemotherapy which had been continued for two years, other new metastatic lesion had not revealed and the target lesion had been slowly increasing. Although we could change the regimen and continue other chemotherapy, the patient didn't wish to suffer new side effect and preferred surgical resection. It was not easy to propose the option of surgical resection, but we thought that the option of surgery could be acceptable when adequate informed consent about the risks, benefits and other therapeutic options are obtained from the patient. After the R0 surgery of Virchow lymph node recurrence, the necessity of chemotherapy may be controversial. The patient understood the risk of recurrence and preferred the follow up without chemotherapy with keeping her quality of life high. In this case, we conducted four times operations during 8 years for Stage IV rectal cancer and its recurrences. As a result, now, there is no recurrence lesion radiologically.

Although surgery alone for severe metastatic recurrence is rarely selected due to the advance of multimodality therapy, it should be considered that surgical resection may bring longer term survival especially in cases with difficulty in management of side effects or necessity of dose reduction chemotherapy. In the recurrent lesion without enough data about long term prognosis, such as para-aortic and Virchow lymph node, we hope that the reports like our approach will be accumulate and make use in decision of therapeutic options in future.

**COMMENTS**

**Case characteristics**

A female patient underwent four times operations during 8 years for Stage IV rectal cancer and its liver, para-aortic, hepatoduodenal ligament and Virchow lymph node metastasis.

**Clinical diagnosis**

Rectal cancer and its recurrence.

**Imaging diagnosis**

Computed tomography showed liver, para-aortic, hepato-duodenal ligament and Virchow lymph node metastatic recurrence.

**Pathological diagnosis**

Histological examination showed moderately differentiated adenocarcinoma.

**Treatment**

Surgical resection and chemotherapy were performed.
Related reports

According to previous reports, the resection of liver metastatic recurrence was acceptable, but the indication of the extrabiliary disease, such as para-aortic, hepatoduodenal ligament and Virchow lymph node is controversial. There are some reports about synchronous or metachronous metastasis of Virchow lymph node which were treated by chemotherapy or chemoradiotherapy (not by surgical resection) and achieved good prognosis.

Explanation of terms

Left supraclavicular lymph node is often called Virchow lymph node. The lymphatic vessels including the thoracic duct arrive at the Virchow lymph node, and this is recognized as being the end of lymph nodes.

Experiences and lessons

Although surgery alone for severe metastatic recurrence is rarely selected due to the advance of multimodality therapy, it should be considered that surgical resection may bring longer term survival especially in cases with difficulty in management of side effects or necessity of dose reduction chemotherapy.

Peer-review

This paper is good.

REFERENCES

1 Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal Carcinoma. 2nd English ed. Tokyo: Kanehara and Co, 2009

2 Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau E, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237 [PMID: 14657227 DOI: 10.1200/JCO.2004.05.113]

3 Hurwitz HI, Fehrenbacher L, Novotny WF, Cartwright LA, Hodi FS, Hayman SL, Caramori G, Baier G, Blanke C, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer: a randomised phase III trial. Lancet 2004; 363: 1056-1064 [PMID: 15101221 DOI: 10.1016/S0140-6736(04)16273-6]

4 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhlouf A, d’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlösser M, Nippgen J, Rougier P, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. J Clin Oncol 2013; 31: 3502-3508 [PMID: 24080660 DOI: 10.1200/JCO.2013.53.1657]

5 Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer 2014; 13: 73-80 [PMID: 24365057 DOI: 10.1016/j.ccc.2013.11.004]

6 Mella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg 1997; 84: 1731-1736 [PMID: 9448628]

7 Scoggins CR, Menzies JO, Blanke CD, Beauchamp RD, Leach SD. Nomoporative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999; 6: 651-657 [PMID: 10560850]

8 Ko S, Jo H, Yun S, Park E, Kim S, Seo HI. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol 2014; 20: 525-531 [PMID: 24574721 DOI: 10.3748/wjg.v20.i2.525]

9 Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Morita Y, Tsuta K, Nishiwaki Y, Kodama T, Ochiai A. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005; 79: 278-82; discussion 283 [PMID: 15620957 DOI: 10.1016/j.thoracros.2004.06.096]

10 Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550 [PMID: 12445064 DOI: 10.1046/j.1365-2168.2002.02274.x]

11 Sugarbaker PH, Chang D, Kojiro M. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res 1996; 81: 89-104 [PMID: 8834578]

12 Min BS, Kim JS, Kim NK, Lim JS, Lee KY, Cho CH, Sohn SK. Extended lymph node dissection for rectal cancer with radiologically diagnosed extrametastatic liver node metastasis. Ann Surg Oncol 2009; 16: 3271-3278 [PMID: 19763693 DOI: 10.1245/s10434-009-0692-1]

13 Min BS, Kim NK, Sohn SK, Cho CH, Lee KY, Baik SH. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol 2008; 97: 136-140 [PMID: 17963247 DOI: 10.1002/jso.20926]

14 Pultanò C, Bodingbauer M, Aldrighetti L, Choti MA, Castillo F, Schulick RD, Gruenberger T, Pawlik TM. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection. Ann Surg Oncol 2012; 19: 435-442 [PMID: 21743977 DOI: 10.1245/s10434-011-1902-1]

15 Sato T. Color Atlas of Applied Anatomy of Lithiologies. Tokyo: Nankodo, 1997

16 Fujie Y, Ikeda M, Seshimo I, Ezumi K, Hata T, Shingai T, Yagi H, Takayama O, Fukunaga H, Ikemura M, Takemasa I, Yamamoto H, Ohue M, Sekimoto M, Hirota S, Monden M. Complete response of highly advanced colon cancer with multiple lymph node metastases to irinotecan combined with UFT: report of a case. Surg Today 2006; 36: 1133-1138 [PMID: 17123148 DOI: 10.1007/s00595-006-3315-5]

17 Ohchi T, Akagi Y, Kinugasa T, Ishibashi Y, Tanaka N, Fujino S, Kibe S, Yuge K, Sasamoto T, Mizobe T, Oka Y, Hong RD, Shirouzu K. Virchow lymph node metastatic recurrence of sigmoid colon cancer with severe lymph node metastases successfully treated using systemic chemotherapy combined with radiotherapy. Anticancer Res 2013; 33: 2935-2940 [PMID: 23780983]
